Riociguat for the Treatment of Pulmonary Arterial Hypertension

Guidelines for the diagnosis and treatment of pulmonary hypertension

Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853

Bosentan Therapy for Pulmonary Arterial Hypertension

Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718

A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension

Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Inhaled Iloprost for Severe Pulmonary Hypertension

Olschewski, H., Simonneau, G., Galiè, N., HIGENBOTTAM, T. W., Naeije, R., Rubin, L. J., Nikkho, S. M., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783

Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension

Ghofrani, H. A., D’Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,393

Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing

Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., Fujita, M., Nakanishi, N., & Miyatake, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,147

An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry

Benza, R. L., Miller, D. P., Barst, R. J., Badesch, D. B., Frost, A., & McGoon, M. D. (2012) · CHEST Journal · doi:10.1378/chest.11-1460 · Cited by 1,107

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,096

To Market, To Market—2013

Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 13

Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit

Grinstein, J., & Gomberg‐Maitland, M. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0547-z · Cited by 13

cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Hoffmann, L. S., & Chen, H. H. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0999-8 · Cited by 13

Constitutively active form of natriuretic peptide receptor 2 ameliorates experimental pulmonary arterial hypertension

Nawa, N., Ishida, H., Katsuragi, S., Baden, H., Takahashi, K., Higeno, R., Torigoe, F., Mihara, S., Narita, J., Miura, K., et al. (2016) · Molecular Therapy: Methods & Clinical Development · doi:10.1038/mtm.2016.44 · Cited by 13

Associations of Exercise Tolerance With Hemodynamic Parameters for Pulmonary Arterial Hypertension and for Chronic Thromboembolic Pulmonary Hypertension

Tsuboi, Y., Tanaka, H., Nishio, R., Sawa, T., Terashita, D., Nakayama, K., Satomi‐Kobayashi, S., Sakai, Y., Emoto, N., & Hirata, K. (2017) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0000000000000257 · Cited by 13

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH

Benza, R. L., Corris, P. A., Ghofrani, H., Kanwar, M. K., McLaughlin, V. V., Raina, A., & Simonneau, G. (2019) · Pulmonary Circulation · doi:10.1177/2045894019837849 · Cited by 13

Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension

Liang, L., Zhang, W., Lin, F. W., Lu, X., Chen, W., Li, X., Zhou, X., Su, R., Wang, L., Zheng, Z., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.014 · Cited by 13

Practical management of riociguat in patients with pulmonary arterial hypertension

Halank, M., Tausche, K., Grünig, E., Ewert, R., & Preston, I. R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619868938 · Cited by 13

Causes and Circumstances of Death in Portopulmonary Hypertension

Sahay, S., Abdi, S. A., Melillo, C. A., Newman, J. E., Dweik, R. A., Heresi, G. A., & Tonelli, A. R. (2021) · Transplantation Direct · doi:10.1097/txd.0000000000001162 · Cited by 13

Measuring and reporting disease progression in subclinical rheumatic heart disease

Karthikeyan, G. (2016) · Heart Asia · doi:10.1136/heartasia-2016-010857 · Cited by 13

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics

Xu, X., Li, H., Wei, Q., Li, X., Shen, Y., Ge, G., Chen, Y., He, K., & Liu, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.742436 · Cited by 12

Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials

Rosenkranz, S., Ghofrani, H.-A., Hoeper, M. M., Langleben, D., Hegab, S., Rahner, C., Richard, J.-F., & McLaughlin, V. V. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.08.018 · Cited by 12

Antagonist molecules in the treatment of angina

Gupta, A. K., Winchester, D. E., & Pepine, C. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.834329 · Cited by 12

Pulmonary Arterial Hypertension in Adults: Novel Drugs and Catheter Ablation Techniques Show Promise? Systematic Review on Pharmacotherapy and Interventional Strategies

Rosanio, S., Pelliccia, F., Gaudio, C., Greco, C., Keylani, A. M., & D'Agostino, D. C. (2014) · BioMed Research International · doi:10.1155/2014/743868 · Cited by 12

Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials

Roofeh, D., Lescoat, A., & Khanna, D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1836156 · Cited by 12

The evolving treatment landscape of pulmonary arterial hypertension

Gale, S. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88610 · Cited by 12

Pulmonary arterial hypertension

Luna‐López, R., Martín, A. R., & Subías, P. E. (2022) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2022.05.010 · Cited by 12

Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes

Jiao, T., Collado, A., Mahdi, A., Tengbom, J., Tratsiakovich, Y., Milne, G. T., Alvarsson, M., Lundberg, J. O., Zhou, Z., Yang, J., et al. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.02.017 · Cited by 12

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction

Falco, L., Brescia, B., Catapano, D., Martucci, M. L., Valente, F., Gravino, R., Contaldi, C., Pacileo, G., & Masarone, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10090388 · Cited by 14

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center

Sulica, R., Fenton, R., & Cefali, F. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0046-y · Cited by 12

Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension

Leuchte, H. H., Baezner, C. J., Baumgartner, R., Muehling, O. M., Neurohr, C., & Behr, J. (2015) · Heart · doi:10.1136/heartjnl-2015-307529 · Cited by 12

Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension

Sharma, M., Pinnamaneni, S., Aronow, W. S., Jozwik, B., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000035 · Cited by 12

Riociguat: A Review of Its Use in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension

Garnock-Jones, K. P. (2014) · Drugs · doi:10.1007/s40265-014-0317-2 · Cited by 12

Therapeutic implications from the pathogenesis of Raynaud’s phenomenon

Herrick, A. L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1279052 · Cited by 12

Severe pulmonary hypertension and right ventricular failure

Neema, P. K., & Kumar, A. (2017) · Indian Journal of Anaesthesia · doi:10.4103/ija.ija_420_17 · Cited by 12

Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy

McMahon, T. J., & Bryan, N. S. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.014 · Cited by 12

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV‐1‐infected adults

DeJesus, E., Saleh, S., Cheng, S., van der Mey, D., Becker, C., Frey, R., Unger, S., & Mueck, W. (2019) · Pulmonary Circulation · doi:10.1177/2045894019848644 · Cited by 12

Therapies that enhance pulmonary vascular NO-signaling in the neonate

Dillard, J., Perez, M., & Chen, B. (2019) · Nitric Oxide · doi:10.1016/j.niox.2019.12.003 · Cited by 12

Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947

Brockunier, L. L., Stelmach, J. E., Guo, J., Spencer, T. W., Rosauer, K. G., Bansal, A., Cai, S., Chen, N., Cummings, J. G., Huang, L., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127574 · Cited by 12

Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure

Liang, W., & Liang, B. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01884-9 · Cited by 12

The −665 C>T polymorphism in the eNOS gene predicts cardiovascular mortality and morbidity in white Europeans

Olivi, L., Gu, Y.-M., Salvi, E., Liu, Y.-P., Thijs, L., Velayutham, D., Yu, J. M., Jacobs, L., D’Avila, F., Petit, T., et al. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2014.66 · Cited by 12

Hypertension pulmonaire : définition, classification et traitements

Jutant, E., & Humbert, M. J. C. (2016) · Biologie Aujourd hui · doi:10.1051/jbio/2016014 · Cited by 12

Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease

Latus, H., Wagner, I., Ostermayer, S. H., Kerst, G., Kreuder, J. G., Schranz, D., & Apitz, C. (2017) · Pediatric Cardiology · doi:10.1007/s00246-017-1667-9 · Cited by 12

Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study

Kuroda, K., Akagi, S., Nakamura, K., Sarashina, T., Ejiri, K., & Ito, H. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.01.013 · Cited by 12

Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease

Gonzales, J., & Fraidenburg, D. R. (2023) · Pharmaceuticals · doi:10.3390/ph16030418 · Cited by 11

Clinical features of pulmonary arterial hypertension associated with systemic sclerosis

Tuhy, T., & Hassoun, P. M. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1264906 · Cited by 11

The Etiology and Management of Critical Acute Right Heart Failure

Luk, A. C., Teijeiro‐Paradis, R., Kochan, A., Billia, F., Douflé, G., Magder, S. A., Mendelson, A. A., McGuinty, C., & Granton, J. T. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.02.006 · Cited by 11

Hypertension precision medicine: the promise and pitfalls of pharmacogenomics

Le, N. N., Frater, I., Lip, S. Z. L., & Padmanabhan, S. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2504865 · Cited by 13

Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies

Thenappan, T., Al‐Naamani, N., Ghio, S., Ghofrani, H., Hassoun, P. M., PRITZKER, M. R., Torbicki, A., Nikkho, S. M., Busse, D., & Preston, I. R. (2020) · Pulmonary Circulation · doi:10.1177/2045894020963836 · Cited by 11

Pulmonary arterial hypertension: guidelines and unmet clinical needs

Giuggioli, D., Bruni, C., Cacciapaglia, F., Dardi, F., Cata, A. D., Papa, N. D., Iannone, F., Lunardi, C., Maglione, W., Molinaro, F., et al. (2021) · Reumatismo · doi:10.4081/reumatismo.2020.1310 · Cited by 11

A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension

Bunclark, K., Doughty, N. J., Michael, A., Abraham, N., Ali, S., Cannon, J. E., Sheares, K. K. K., Speed, N., Taboada, D., Toshner, M. R., et al. (2021) · Pulmonary Circulation · doi:10.1177/2045894021995055 · Cited by 11

Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension

Aulak, K. S., Abdi, S. A., Li, L., Crabb, J. S., Ghosh, A., Willard, B. B., Stuehr, D. J., Crabb, J. W., Dweik, R. A., & Tonelli, A. R. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00500.2020 · Cited by 11

Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase

Sharma, A., Choi, J. S. Y., Sim, L., Dey, A., Mohan, M., Kantharidis, P., Dietz, L., Sandner, P., & de Haan, J. B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1220095 · Cited by 11

Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension

Caccamo, M. A., Harrell, F. E., & Hemnes, A. R. (2023) · Pulmonary Circulation · doi:10.1002/pul2.12271 · Cited by 11

Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study

Langleben, D., Galiè, N., He, J., Huang, Y., Humbert, M. J. C., KEOGH, A. M., Rubin, L. J., Zhou, D., Curram, J., Davie, N. J., et al. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.12.001 · Cited by 11

Novel Medical Therapies for Pulmonary Arterial Hypertension

O’Connell, C., O’Callaghan, D. S., & Humbert, M. J. C. (2013) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2013.08.002 · Cited by 11

Parenteral Prostanoid Use at a Tertiary Referral Center

Hay, B. R., Pugh, M. E., Robbins, I. M., & Hemnes, A. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1051 · Cited by 11

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Bishop, B. M. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130777 · Cited by 11

Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension

Amirjanians, M., Egemnazarov, B., Sydykov, A. S., Kojonazarov, B. K., Brandes, R. P., Luitel, H., Pradhan, K., Stasch, J., Redlich, G., Weißmann, N., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16769 · Cited by 11

Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data

Khanna, D., Jahreis, A., & Fürst, D. E. (2017) · Journal of Scleroderma and Related Disorders · doi:10.5301/jsrd.5000267 · Cited by 11

An update on the diagnosis and treatment of pediatric pulmonary hypertension

Olguntürk, R. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1757071 · Cited by 11

Cardiovascular Diseases That Have Emerged From the Darkness

Maron, B. J., Maron, M. S., Maurer, M. S., Rowin, E. J., Maron, B. A., & Galiè, N. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021095 · Cited by 11

Advanced Therapy in Eisenmenger Syndrome

Hjortshøj, C. S., Jensen, A. S., & Søndergaard, L. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000107 · Cited by 11

Pulmonary arterial hypertension and associated conditions

Ataya, A., Patel, S., Cope, J. M., & Alnuaimat, H. (2016) · Disease-a-Month · doi:10.1016/j.disamonth.2016.03.006 · Cited by 11

Riociguat and sildenafil for pulmonary hypertension: similarity and difference

Шмальц, А. А., & Gorbachevskiy, S. V. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-1-85-91 · Cited by 11

Right Ventricular Function is Associated With Quality of Life in Patients With Systemic Lupus Erythematosus Associated Pulmonary Arterial Hypertension

Wang, H., Wang, Q., Tian, Z., Guo, X., Lai, J., Li, M., Zhao, J., Liu, Y., Zeng, X., & Fang, Q. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.09.002 · Cited by 11

Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis

Derichs, N., Taylor‐Cousar, J. L., Davies, J. C., Fajac, I., Tullis, E. D., Nazareth, D. S., Downey, D. G., Rosenbluth, D., Malfroot, A., Saunders, C. J., et al. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.07.015 · Cited by 11

Portopulmonary hypertension: Formidable dual threat versus hopeful dual therapy

Krowka, M. J., & Cartin‐Ceba, R. (2014) · Liver Transplantation · doi:10.1002/lt.23885 · Cited by 11

Amelioration of right ventricular function after hybrid therapy with riociguat and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension

Tsugu, T., Murata, M., Kawakami, T., Kataoka, M., Nagatomo, Y., Tsuruta, H., Itabashi, Y., Maekawa, Y., & Fukuda, K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.331 · Cited by 11

Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients

Cui, X., Lu, W., Zhang, D., Qie, L., Li, H., Li, X., Liu, H., & Ji, Q. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.991586 · Cited by 10

Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications

Novara, M. E., Martino, E. D., Stephens, B., Nayrouz, M., Vitulo, P., Carollo, A., & Provenzani, A. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00453-x · Cited by 10

Renal dysfunction and outcomes in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an individual participant data meta-analysis

Meservey, A., Al‐Naamani, N., Minhas, J., Fritz, J. S., Appleby, D. H., Baudry, G., Girerd, N., Feng, R., Kawut, S. M., & Moutchia, J. (2025) · European Respiratory Journal · doi:10.1183/13993003.02400-2024 · Cited by 10

Metabolic Reprogramming Intermediates of Glucose Regulate Macrophage Polarization: An Important Direction for Ameliorating Pulmonary Vascular Remodeling

Wang, J., Yuan, R., Zhang, S., Xu, Z., & Song, L. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s541649 · Cited by 10

Update on Systemic Sclerosis

McCray, C. J., & Mayes, M. D. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0526-0 · Cited by 10

Prospects for improving outcomes in systemic sclerosis‐related pulmonary hypertension

Thakkar, V., Nikpour, M., Stevens, W., & Proudman, S. (2015) · Internal Medicine Journal · doi:10.1111/imj.12691 · Cited by 10

Hemodynamics Should Be the Primary Approach to Diagnosing, Following, and Managing Pulmonary Arterial Hypertension

Maron, B. A. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.09.021 · Cited by 10

CCTTT Pentanucleotide Repeats in Inducible Nitric Oxide Synthase Gene Expression in Patients With Pulmonary Arterial Hypertension

Villar, A. B., Pousada, G., Pombo, C. V., Fernández, M. N., Martínez, J. M. C., & Valverde, D. (2014) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2014.03.006 · Cited by 10

Vasodilatory action of trans‐4‐methoxy‐β‐nitrostyrene in rat isolated pulmonary artery

Arruda‐Barbosa, L., Vasconcelos‐Silva, A. A., Borges, R. S., Duarte, G. I. B. P., Magalhães, P. J. C., & Lahlou, S. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13467 · Cited by 10

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study

Yang, S., Yang, Y., Zhang, Y., Kuang, T., Gong, J., Li, J., Li, Y., Wang, J., Guo, X., & Miao, R. (2021) · ERJ Open Research · doi:10.1183/23120541.00082-2021 · Cited by 10

Gemfibrozil derivatives as activators of soluble guanylyl cyclase – A structure-activity study

Gayler, K. M., Quintana, J. M., MATTKE, J. D., Plunk, M. A., Kostyo, J. H., Karunananthan, J. W., Nguyen, H., Shuda, M. R., Ferreira, L. D., Baker, H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113729 · Cited by 10

Vericiguat for the treatment of heart failure with reduced ejection fraction

Siddiqi, A. K., Greene, S. J., Fudim, M., Mentz, R. J., Butler, J., & Khan, M. S. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2189101 · Cited by 10

Heterogeneity of treatment effects by risk in pulmonary arterial hypertension

Pan, H., McClelland, R. L., Moutchia, J., Appleby, D. H., Fritz, J. S., Holmes, J. H., Minhas, J., Palevsky, H. I., Urbanowicz, R. J., Kawut, S. M., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00190-2023 · Cited by 10

Recent Advances in the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases

Smukowska-Gorynia, A., Gościniak, W., Woźniak, P., Iwańczyk, S., Jaxa-Kwiatkowska, K., Sławek-Szmyt, S., Janus, M., Paluszkiewicz, J., & Mularek‐Kubzdela, T. (2023) · Pharmaceuticals · doi:10.3390/ph16091252 · Cited by 10

Emerging therapeutic targets in systemic sclerosis

O’Reilly, S. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02424-w · Cited by 10

Comparative Effectiveness of Sotatercept and Approved Add-On Pulmonary Arterial Hypertension Therapies: A Systematic Review and Network Meta-Analysis

Pitre, T., Desai, K., Mah, J. C., Zeraatkar, D., & Humbert, M. J. C. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202311-942oc · Cited by 10

Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment

Simeone, B., Maggio, E., Schirone, L., Rocco, E., Sarto, G., Spadafora, L., Bernardi, M., D’Ambrosio, L., Forte, M., Vecchio, D., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1439411 · Cited by 10

New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review

Rasheed, A., Aslam, S., Sadiq, H. Z., Ali, S., Syed, R., & Panjiyar, B. K. (2024) · Cureus · doi:10.7759/cureus.68117 · Cited by 10

Portopulmonary hypertension: Diagnosis, clinical features, and medical therapy

Bartolome, S. (2014) · Clinical Liver Disease · doi:10.1002/cld.401 · Cited by 10

Riociguat for pulmonary hypertension

Cannon, J. E., & Pepke‐Żaba, J. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.893818 · Cited by 10

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension

Murata, M., Kawakami, T., Kataoka, M., Kohno, T., Itabashi, Y., & Fukuda, K. (2017) · Pulmonary Circulation · doi:10.1177/2045893217746111 · Cited by 10

A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease

Fathallah, M., & Krasuski, R. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.07.017 · Cited by 10

PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM

Volkov, A. V., & Martynyuk, T. V. (2018) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2018-474-485 · Cited by 10

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications

Elliott, C. G., Austin, E. D., Badesch, D. B., Badlam, J. B., Benza, R. L., Chung, W. K., Farber, H. W., Feldkircher, K., Frost, A., Poms, A. D., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019851696 · Cited by 10

Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives

Boutou, A., & Pitsiou, G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1727446 · Cited by 10

Clinical trial design in phase 2 and 3 trials for pulmonary hypertension

Nikkho, S. M., Fernandes, P., White, R. J., Deng, C. Q., Farber, H. W., & Corris, P. A. (2020) · Pulmonary Circulation · doi:10.1177/2045894020941491 · Cited by 10

Advantages and limitations of initial combination therapy in pulmonary arterial hypertension patients in Russia

Shmalts, A. A., & Gorbachevsky, S. V. (2020) · Terapevticheskii arkhiv · doi:10.26442/00403660.2020.12.000840 · Cited by 10

Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations

Lareo, A., Nuche, J., Ropero, M. J. C., Arribas, F., Oliver, E., & Subías, P. E. (2021) · Kardiologia Polska · doi:10.33963/kp.15928 · Cited by 10

Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials

Moghaddam, N., Malhi, N., & Toma, M. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.07.003 · Cited by 10

Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications)

Téllez, L., & Guerrero, A. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01149-3 · Cited by 10

Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy

Brida, M., Price, L., McCabe, C., Alonso-González, R., Wort, S. J., Kempny, A., Dimopoulos, K., Gatzoulis, M. Α., & Nashat, H. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1606222 · Cited by 10

Therapeutic Targeting of the Soluble Guanylate Cyclase

Makrynitsa, G. I., Zompra, A. A., Argyriou, A. I., Spyroulias, G. A., & Topouzis, S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190108095851 · Cited by 10

Application of the REVEAL risk score calculator 2.0 in the PATENT study

Benza, R. L., Farber, H. W., Frost, A., Ghofrani, H.-A., Corris, P. A., Lambelet, M., Nikkho, S. M., Meier, C., & Hoeper, M. M. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.03.034 · Cited by 10

Traitement de l’hypertension artérielle pulmonaire

Sitbon, O., Savale, L., Jaïs, X., Montani, D., Humbert, M. J. C., & Simonneau, G. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.07.011 · Cited by 10

Pulmonary arterial hypertension in congenital heart disease

Frogoudaki, A., & Gatzoulis, M. Α. (2018) · Continuing Cardiology Education · doi:10.1002/cce2.74 · Cited by 10

Stimulation of soluble guanylate cyclase activity with riociguat promotes angiogenesis and improves neovascularization after limb ischemia

Dhahri, W., Dussault, S., Raguema, N., Desjarlais, M., & Rivard, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.017 · Cited by 9

Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy

Magavern, E. F., Kapil, V., Saxena, M., Gupta, A. K., & Caulfield, M. J. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319220 · Cited by 9

Treatment of pulmonary hypertension after seven world symposia

Estrada, R. A., Sahay, S., & Tonelli, A. R. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251342898 · Cited by 9

Vascular Metabolic Mechanisms of Pulmonary Hypertension

Shi, X.-F., & Su, Y.-C. (2020) · Current Medical Science · doi:10.1007/s11596-020-2198-9 · Cited by 9

Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials

Tan, Z. W., Wu, P., Zhu, T., Su, W., & Fang, Z. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102144 · Cited by 9

Advances in targeted therapy for pulmonary arterial hypertension in children

Li, L., Zhu, X., Chen, X., Gao, J., Ding, C., Xu, M., Zhang, M., & Ma, S. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04750-y · Cited by 9

Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

Rubin, L. J., Galiè, N., Grimminger, F., Grünig, E., Humbert, M. J. C., Jing, Z., KEOGH, A. M., Langleben, D., Fritsch, A., Menezes, F., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00090614 · Cited by 221

Riociguat for the Treatment of Pulmonary Hypertension: A Meta-analysis of Randomized Controlled Trials

Alrifai, A., Garnet, B., Shah, V., & Lit, L. (2015) · CHEST Journal · doi:10.1378/chest.2281793

Riociguat in Combination With Endothelin Receptor Antagonists (ERAs) for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of PATENT

Hill, N. S., & Sood, N. (2015) · CHEST Journal · doi:10.1378/chest.2281116

September 2013 pulmonary journal club: riociguat; pay the doctor

Robbins, R. (2013) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc116-13

Influence of riociguat treatment on pulmonary arterial hypertension

Zhao, R., & Jiang, Y. (2018) · Herz · doi:10.1007/s00059-018-4697-z · Cited by 8